Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂ Disease
Spironolactone for Heart Failure with Preserved Ejection Fraction
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF
